DRNA - Dicerna Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $3.46. This is a potential upside of $3.46 (0%) from yesterday's end of day stock price of $0.

Dicerna Pharmaceuticals's activity chart (see below) currently has 99 price targets and 62 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 76.59% with an average time for these price targets to be met of 309.55 days.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 10-Dec-2021. First documented stock forecast 13-Mar-2015.

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

Since 10-Dec-2021

$38.25

$0.03 (0.08%)

4 years 1 months 9 days ago
(10-Dec-2021)

1/2 (50%)

$0.34 (0.90%)

101

Hold

Since 19-Nov-2021

$30

$-8.22 (-21.51%)

$30

4 years 2 months ago
(19-Nov-2021)

2/3 (66.67%)

$-7.92 (-20.89%)

250

Hold

Since 18-Nov-2021

$35

$-3.22 (-8.42%)

$35

4 years 2 months 1 days ago
(18-Nov-2021)

3/6 (50%)

$-3.03 (-7.97%)

168

Hold

Since 18-Nov-2021

$38

$-0.22 (-0.58%)

$42

4 years 2 months 1 days ago
(18-Nov-2021)

8/10 (80%)

$-0.03 (-0.08%)

260

Buy

Since 06-Nov-2018

$25

$-13.22 (-34.59%)

4 years 5 months 9 days ago
(10-Aug-2021)

5/8 (62.5%)

$2.81 (12.66%)

195

Show more analysts

Please expand the browser size to see the chart

What is DRNA (Dicerna Pharmaceuticals) average time for price targets to be met?

On average it took 309.55 days on average for the stock forecasts to be realized with a an average price target met ratio 76.59

Which analyst has the current highest performing score on DRNA (Dicerna Pharmaceuticals) with a proven track record?

MAYANK MAMTANI

Which analyst has the most public recommendations on DRNA (Dicerna Pharmaceuticals)?

Mayank Mamtani works at B. RILEY and has 2 price targets and 1 ratings on DRNA

Which analyst is the currently most bullish on DRNA (Dicerna Pharmaceuticals)?

Keay Nakae with highest potential upside - $0.03

Which analyst is the currently most reserved on DRNA (Dicerna Pharmaceuticals)?

Edward Nash with lowest potential downside - -$18.22

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?